Compare KSS & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KSS | VIR |
|---|---|---|
| Founded | 1962 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 1995 | 2019 |
| Metric | KSS | VIR |
|---|---|---|
| Price | $14.91 | $9.10 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 15 | 7 |
| Target Price | $15.31 | ★ $19.43 |
| AVG Volume (30 Days) | ★ 4.7M | 1.5M |
| Earning Date | 05-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.58% | N/A |
| EPS Growth | ★ 142.86 | 17.49 |
| EPS | ★ 2.38 | N/A |
| Revenue | N/A | ★ $68,556,000.00 |
| Revenue This Year | N/A | $270.22 |
| Revenue Next Year | $0.21 | N/A |
| P/E Ratio | $5.95 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.09 | $4.16 |
| 52 Week High | $25.22 | $11.66 |
| Indicator | KSS | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 59.35 | 45.54 |
| Support Level | $13.91 | $8.48 |
| Resistance Level | $16.82 | $10.29 |
| Average True Range (ATR) | 0.77 | 0.41 |
| MACD | 0.31 | 0.03 |
| Stochastic Oscillator | 74.28 | 40.65 |
Kohl's is the second-largest traditional US department store company by sales. It has about 1,150 stores in 49 states and offers moderately priced private-label (31% of 2025 sales) and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most (about 80%) of its stores are in strip centers. Kohl's also has a large digital sales operation (29% of 2025 sales). Women's apparel is the retailer's largest category, having generated 24% of its 2025 sales. Kohl's is headquartered in Menomonee Falls, Wisconsin, and was founded in 1962.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.